I JMIR出版物一种移动健康干预改善冠心病患者的药物依从性和健康结局卡塔尔世界杯8强波胆分析:随机对照试验%A Ni,Zhao %A Wu,Bei %A Yang,Qing %A Yan,Lijing L %A Liu,Changqing %A Shaw,Ryan J %+耶鲁大学医学院，康涅狄格州纽黑文，06510，美国，1 646 617 2232,zhao.ni@yale.edu %K mHealth %K药物坚持%K冠状动脉疾病%K血压%K中国%K随机对照试验%D 2022 %7 9.3.2022 %9原创论文%J J医学互联网Res %G英语%X背景:许多慢性疾病的治疗涉及长期药物治疗，但寻找有效方法提高药物依从性以促进良好的健康结果是一项持续的挑战。心脏保护药物可以防止冠心病患者有害血栓、心血管症状和不良治疗结果的扩大，如无法控制的高血压和高脂血症。然而，据报道，冠心病患者对心脏保护药物的依从性差是一个全球性的健康问题，在中国尤其如此。目的:本研究旨在评估使用2个移动应用程序的移动健康(mHealth)干预的有效性，以改善药物依从性和健康结果。方法:在成都某大学附属医学中心进行随机、安慰剂对照、两臂平行研究。参与者是通过传单和保健提供者推荐招募的。每个参与者被观察了90天，其中包括60天的移动健康干预期和30天的非干预随访期。研究协调员分别使用微信和Message Express发送教育材料和服药提醒。 Participants used WeChat to receive both the educational materials and reminders. Participants in the control group only received educational materials. This study received ethics approval from the Duke Health Institutional Review Board (Pro00073395) on May 5, 2018, and was approved by West China Hospital (20170331180037). Recruitment began on May 20, 2018. The pilot phase of this study was registered on June 8, 2016, and the current, larger-scale study was retrospectively registered on January 11, 2021 (ClinicalTrials.gov). Results: We recruited 230 patients with coronary heart disease. Of these patients, 196 completed the baseline survey and received the intervention. The majority of participants were married (181/196, 92.4%), male (157/196, 80.1%), and lived in urban China (161/196, 82.1%). Participants’ average age was 61 years, and half were retired (103/191, 53.9%). More than half the participants (121/196, 61.7%) were prescribed at least 5 medications. The mean decrease in medication nonadherence score was statistically significant at both 60 days (t179=2.04, P=.04) and 90 days (t155=3.48, P<.001). Systolic blood pressure and diastolic blood pressure decreased in the experimental group but increased in the control group. The mean decrease in diastolic blood pressure was statistically significant at both 60 days (t160=2.07, P=.04) and 90 days (t164=2.21, P=.03). The mean decrease in systolic blood pressure was significantly different in the groups at 90 days (t165=3.12, P=.002). Conclusions: The proposed mHealth intervention can improve medication adherence and health outcomes, including systolic blood pressure and diastolic blood pressure. Trial Registration: ClinicalTrials.gov NCT02793830; https://clinicaltrials.gov/ct2/show/NCT02793830 and ClinicalTrials.gov NCT04703439; https://clinicaltrials.gov/ct2/show/NCT04703439 %M 35262490 %R 10.2196/27202 %U //www.mybigtv.com/2022/3/e27202 %U https://doi.org/10.2196/27202 %U http://www.ncbi.nlm.nih.gov/pubmed/35262490